Mesoblast considers plans for COVID treatment after Novartis exits deal

Submitted by admin on December 20, 2021 - 10:48am

Source:

Biopharma Reporter

News Tags:

Headline:

snippet:

After disappointing results in Phase III trials, Novartis chooses to terminate agreement to develop COVID-19 treatment alongside Mesoblast.

Search form